Evidence map›Paper›PMID 36644564›Full record

ArticleAtherosclerosis plus2022

Role of an automated screening tool for familial hypercholesterolemia in patients with premature coronary artery disease.

Antti Jokiniitty, Markku Eskola, Tanja Saarela, Heini Huhtala, Saara Metso

Open access · goldAbstract read
In one paragraph

Article in Atherosclerosis plus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Antti JokiniittyFaculty of Medicine and Health Technology, Tampere University, Arvo Ylpön katu 34, 33520, Tampere, Finland.
Markku EskolaFaculty of Medicine and Health Technology, Tampere University, Arvo Ylpön katu 34, 33520, Tampere, Finland.
Tanja SaarelaFaculty of Medicine and Health Technology, Tampere University, Arvo Ylpön katu 34, 33520, Tampere, Finland.
Heini HuhtalaFaculty of Social Sciences, Tampere University, Arvo Ylpön katu 34, 33520, Tampere, Finland.
Saara MetsoFaculty of Medicine and Health Technology, Tampere University, Arvo Ylpön katu 34, 33520, Tampere, Finland.
Tampere University · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aims: To validate an automated screening tool for patients with premature coronary artery disease (CAD) and high total cholesterol or LDL-C levels and assess if it would provide clinicians with additional support in identifying patients with Familial Hypercholesterolemia (FH). Methods: An IT-based automated screening tool based on coronary angiography data recorded in the KARDIO registry and laboratory values was validated among patients undergone coronary angiography in the Heart Hospital at Tampere University Hospital between 2007 and 2017 fulfilling the criteria of premature CAD (men <55 years and women <60 years) and history of high total cholesterol (>8 mmol/l) or LDL-cholesterol (>5 mmol/l) levels. Electronic health records were retrospectively analyzed to determine if these patients had been diagnosed with FH based on clinical features and whether genetic testing had been conducted. Results: The automated screening tool identified 0.7% (211/28295) of all patients undergone coronary angiography and revealed history of high cholesterol in 8% (211/2678) of patients with premature CAD during the study period. Fifty-one percent (107/211) of these patients fulfilled the clinical criteria for probable/definite FH based on the Dutch Lipid Clinic Network (DLCN) criteria.None of the patients had been diagnosed with FH based on clinical criteria before or after diagnosis of CAD. Thirteen percent of patients (n = 14) with probable/definite FH had been tested for genetic mutations of FH before or after CAD, five (36%) of them having a pathogenic FH variant. Two patients were referred to cascade screening. Conclusions: FH was underdiagnosed among the population studied. An automated screening tool in cardiac care could provide additional support for clinicians in diagnosing patients potentially having FH.

Indexed as

Coronary artery diseaseFamilial hypercholesterolemiaScreening

Identifiers

PMID36644564
PMCPMC9833226
OpenAlexW4206604191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.